High Incidence of Metabolic Syndrome Components in Lichen Planus Patients: A Prospective Cross-Sectional Study

Zeinab Aryanian, Azar Shirzadian, Parvaneh Hatami, Hadiyeh Dadras, Zeinab Aryanian, Azar Shirzadian, Parvaneh Hatami, Hadiyeh Dadras

Abstract

Background: Lichen planus (LP) is a chronic inflammatory dermatosis, involving the skin, appendages, and mucous membranes. There is a growing body of evidence about higher risk of metabolic syndrome and dyslipidemia in some dermatoses including LP.

Aim: To evaluate lipid profile, leptin, and CRP status among Iranian LP patients, compared to healthy controls, and peruse the relationship between abnormal values of these parameters with the disease duration and physical characteristics of patients.

Methods: 40 LP patients and 40 age- and sex-matched healthy controls were enrolled in the study. Data on weight, height, lipid profile, leptin, and CRP values were recorded and compared.

Results: The mean values for leptin, CRP, and lipid profile parameters (except for HDL) were higher in patients, compared to controls. Total cholesterol level was negatively associated with disease duration in patients (P value: 0.039, r: -0.33). Serum leptin level was positively correlated with BMI both in patients and controls (P value: 0.037 and 0.003, respectively). In the patient group, LDL level, although insignificant, was higher in men, but HDL and leptin levels were significantly higher in women in comparison with men (P value: 0.018).

Conclusion: Screening of LP patients in regard to their lipid profile might be more reasonable in men or those who have other cardiovascular risk factors to prevent morbidity and mortality in result of developing cardiovascular events.

Conflict of interest statement

The authors declare no conflicts of interest regarding the publication of this article.

Copyright © 2022 Zeinab Aryanian et al.

Figures

Figure 1
Figure 1
Lipid profile of participants regarding gender.

References

    1. Arias-Santiago S., Eisman A. B., Fernandez J. A. Cardiovascular risk factors in patients with lichen planus. The American Journal of Medicine . 2011;124:543–548.
    1. Özkur E., Uğurer E., Altunay İK. Dyslipidemia in lichen planus: a case-control study. Sisli Etfal Hastanesi tip bulteni . 2020;54(1):62–66. doi: 10.14744/SEMB.2018.48108.
    1. Kar B. R., Panda M., Patro N. Metabolic derangements in lichen planus - a case control study. Journal of Clinical and Diagnostic Research: Journal of Clinical and Diagnostic Research . 2016;10(11):WC01–WC03. doi: 10.7860/JCDR/2016/21993.8818.
    1. Abrahão-Machado E. C. F., Mendonça J. A., Arruda A. C. B. B., Nucci L. B., Santos M. A. S. D. Analysis of cardiovascular risk and carotid intima-media thickness in patients with psoriasis. Anais Brasileiros de Dermatologia . 2020;95(2):150–157.
    1. Ghiasi M., Nouri M., Abbasi A., Hatami P., Abbasi M. A., Nourijelyani K. Psoriasis and increased prevalence of hypertension and diabetes mellitus. Indian Journal of Dermatology . 2011;56(5):533–536. doi: 10.4103/0019-5154.87149.
    1. Ying J., Xiang W., Qiu Y., Zeng X. Risk of metabolic syndrome in patients with lichen planus: a systematic review and meta-analysis. PLoS One . 2020;15(8) doi: 10.1371/journal.pone.0238005.e0238005
    1. Reaven G. The metabolic syndrome or the insulin resistance syndrome? different names, different concepts, and different goals. Endocrinology and Metabolism Clinics of North America . 2004;33(2):283–303. doi: 10.1016/j.ecl.2004.03.002.
    1. Dreiher J., Shapiro J., Cohen A. D. Lichen planus and dyslipidaemia: a case-control study. British Journal of Dermatology . 2009;161(3):626–629. doi: 10.1111/j.1365-2133.2009.09235.x.
    1. Myers M. G., Münzberg H., Leinninger G. M., Leshan R. L. The geometry of leptin action in the brain: more complicated than a simple ARC. Cell Metabolism . 2009;9(2):117–123. doi: 10.1016/j.cmet.2008.12.001.
    1. Schwartz M. W., Woods S. C., Porte D., Seeley R. J., Baskin D. G. Central nervous system control of food intake. Nature . 2000;404(6778):661–671. doi: 10.1038/35007534.
    1. Rosenbaum M., Leibel R. L. The role of leptin in human physiology. New England Journal of Medicine . 1999;341(12):913–915. doi: 10.1056/nejm199909163411211.
    1. Osegbe I., Okpara H., Azinge E. Relationship between serum leptin and insulin resistance among obese Nigerian women. Annals of African Medicine . 2016;15(1):14–19. doi: 10.4103/1596-3519.158524.
    1. Aryanian Z., Shahabandaz H., Abdollahzadeh Sangrody M., et al. Carotid Doppler ultrasound evaluation in patients with lichen Planus. Iran Journal of Dermatology . 2019;22:133–138.
    1. Ghandi N., Daneshmand R., Hatami P., et al. A randomized trial of diphenylcyclopropenone (DPCP) combined with anthralin versus DPCP alone for treating moderate to severe alopecia areata. International Immunopharmacology . 2021;99 doi: 10.1016/j.intimp.2021.107971. Epub 2021 Jul 20. PMID: 34298402.107971
    1. Hallaji Z., Lajevardi V., Abedini R., et al. Serum leptin levels in psoriatic patients with non-alcoholic fatty liver disease. Iranian Journal of Dermatology . 2016;19:125–130.
    1. Aryanian Z., Shojaee N., Goodarzi A., Shirzadian A., Hatami P. Influence of narrow-band ultra violet B phototherapy on homocysteine status: a prospective study of patients with different cutaneous disorders. Photobiomodulation, Photomedicine, and Laser Surgery . 2021;39(9):607–611. doi: 10.1089/photob.2021.0025. PMID: 34546111.
    1. Hatami P., Balighi K., Nicknam Asl H., Aryanian Z. COVID vaccination in patients under treatment with rituximab: a presentation of two cases from Iran and a review of the current knowledge with a specific focus on pemphigus. Dermatologic Therapy . 2021 doi: 10.1111/dth.15216. Epub ahead of print. PMID: 34811862.e15216
    1. Al Bazzal A., Hatami P., Abedini R., Etesami I., Aryanian Z., Ghandi N. A prospective comparative study of two regimens of diphenylcyclopropenone (DPCP) in the treatment of alopecia areata. International Immunopharmacology . 2021;101(Pt B) doi: 10.1016/j.intimp.2021.108186. Epub ahead of print. PMID: 34710658.108186
    1. Aryanian Z., Balighi K., Daneshpazhooh M., et al. Rituximab exhibits a better safety profile when used as a first line of treatment for pemphigus vulgaris: a retrospective study. International Immunopharmacology . 2021;96 doi: 10.1016/j.intimp.2021.107755. Epub 2021 May 24. PMID: 34162136.107755
    1. Akhyani M., Hatami P., Yadegarfar Z., Ghannadan A. Pigmented colloid milium associated with exogenous ochronosis in a farmer with long-term exposure to fertilizers. Journal of Dermatological Case Reports . 2015;9(2):42–45. doi: 10.3315/jdcr.2015.1197. PMID: 26236412.
    1. Lai Y. C., Yew Y. W., Schwartz R. A. Lichen planus and dyslipidemia: a systematic. 2013.
    1. Conic R. R. Z., Piliang M., Bergfeld W., Atanaskova-Mesinkovska N. Association of lichen planopilaris with dyslipidemia. JAMA Dermatology . 2018;154(9):1088–1089. doi: 10.1001/jamadermatol.2018.1749.
    1. Aniyan K. Y., Guledgud M. V., Patil K. Alterations of serum lipid profile patterns in oral lichen planus patients: a case-control study. Contemporary Clinical Dentistry . 2018;9(Suppl 1):S112–S121. doi: 10.4103/ccd.ccd_111_18.
    1. Lai Y. C., Yew Y. W., Schwartz R. A. Lichen planus and dyslipidemia: a systematic review and meta-analysis of observational studies. International Journal of Dermatology . 2016;55(5):e295–e304. doi: 10.1111/ijd.13234.
    1. Carbone M., Arduino P., Carrozzo M., et al. Course of oral lichen planus: a retrospective study of 808 northern Italian patients. Oral Diseases . 2009;15(3):235–243. doi: 10.1111/j.1601-0825.2009.01516.x.
    1. Gonzalez-Gay M. A., Gonzalez-Juanatey C., Lopez-Diaz M. J., et al. HLA-DRB1 and persistent chronic inflammation contribute to cardiovascular events and cardiovascular mortality in patients with rheumatoid arthritis. Arthritis & Rheumatism . 2007;57(1):125–132. doi: 10.1002/art.22482.
    1. Baykal L., Arıca D. A., Yaylı S., et al. Prevalence of metabolic syndrome in patients with mucosal lichen planus: a case-control study. American Journal of Clinical Dermatology . 2015;16(5):439–445. doi: 10.1007/s40257-015-0142-8.
    1. Ridker P. M., Hennekens C. H., Buring J. E., Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. New England Journal of Medicine . 2000;342(12):836–843. doi: 10.1056/nejm200003233421202. [PubMed] [Google Scholar]
    1. Lagrand W. K., Visser C. A., Hermens W. T., et al. C-reactive protein as a cardiovascular risk factor. Circulation . 1999;100(1):96–102. doi: 10.1161/01.cir.100.1.96.
    1. Gerdes S., Osadtschy S., Rostami-Yazdi M., Buhles N., Weichenthal M., Mrowietz U. Leptin, adiponectin, visfatin and retinol-binding protein-4 - mediators of comorbidities in patients with psoriasis? Experimental Dermatology . 2011;21(1):43–47. doi: 10.1111/j.1600-0625.2011.01402.x.
    1. Considine R. V., Sinha M. K., Heiman M. L., et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. New England Journal of Medicine . 1996;334(5):292–295. doi: 10.1056/nejm199602013340503.
    1. Thomas T., Burguera B., Melton L. J., et al. Relationship of serum leptin levels with body composition and sex steroid and insulin levels in men and women. Metabolism . 2000;49(10):1278–1284. doi: 10.1053/meta.2000.9519.
    1. Grao-Cruces E., Varela L. M., Martin M. E., Bermudez B., Montserrat-de la Paz S. High-density lipoproteins and mediterranean diet: a systematic review. Nutrients . 2021;13(3):p. 955. doi: 10.3390/nu13030955.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren